The $30 million common share purchase agreement with Lincoln Park Capital Fund will provide Cybin with additional capital to strengthen its cash position and advance its drug development programs. This news is directly related to Cybin and is likely to have a positive impact on its stock price in the short term, as it demonstrates the company's ability to secure funding and continue its growth.